Most Popular
-
1
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
2
First snow to fall in Seoul on Wednesday
-
3
S. Korea not to attend Sado mine memorial: foreign ministry
-
4
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
5
Man convicted after binge eating to avoid military service
-
6
Wealthy parents ditch Korean passports to get kids into international school
-
7
Toxins at 622 times legal limit found in kids' clothes from Chinese platforms
-
8
[Weekender] Korea's traditional sauce culture gains global recognition
![[Weekender] Korea's traditional sauce culture gains global recognition](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050153_0.jpg&u=20241123224317)
-
9
BLACKPINK's Rose stays at No. 3 on British Official Singles chart with 'APT.'
-
10
Korea to hold own memorial for forced labor victims, boycotting Japan’s
![[Weekender] Korea's traditional sauce culture gains global recognition](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050153_0.jpg&u=20241123224317)
Samsung Bioepis seeks approval for Humira biosimilar in Korea
By 이지윤Published : Sept. 26, 2016 - 15:02
[THE INVESTOR] Samsung Bioepis is seeking regulatory approval to sell its biosimilar drug referencing AbbVie’s top-selling rheumatoid drug Humira in South Korea.
According to industry sources on Sept. 26, the biopharma development unit of Samsung Group has recently submitted its application to the Korean authorities for the sales approval of its Humira biosimilar, called SB5.
Sources said the final approval could be granted in the first half of next year.
According to industry sources on Sept. 26, the biopharma development unit of Samsung Group has recently submitted its application to the Korean authorities for the sales approval of its Humira biosimilar, called SB5.
Sources said the final approval could be granted in the first half of next year.
Humira, together with Enbrel and Remicade, are considered the top-selling biotech drugs that block chemicals linked to inflammation.
Samsung Bioepis is already selling its own biosimilar versions of Enbrel and Remicade in South Korea and Europe.
Adding to the three drugs, the company is also waiting for the approval for its SB3, a biosimilar for Roche’s breast cancer drug Herceptin, in South Korea.
By Lee Ji-yoon (jylee@heraldcorp.com)
![[More than APT] Residents, architects together design homes](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/11/24/20241124050036_0.jpg&u=)
